FINORA Nutra manufactures nutraceuticals to pharmaceutical standard — traced from botanical to bottle, and independently verified against every claim on the label.

The supplement industry is regulated as food. FINORA is not built that way. Every formulation is designed to a pharmaceutical monograph — with defined actives, defined tolerances, and defined contaminants.
Certificates of analysis are attached to every bottle by lot number, and are searchable in full. If we cannot verify a claim, it does not appear on the label.
HPLC and FTIR fingerprint against reference standard.
Assayed within ±2% of label claim, retested at 24 months.
Heavy metals, solvents, pesticides, mycotoxins, microbials.
From botanical to bottle, every FINORA product moves through four documented stages — each one gated by a signature and a certificate.

Botanicals and isolates traced to a single supplier of origin. Each batch is accompanied by a certificate of analysis before it enters our facility.
Ratios are set by our clinical advisory board, then modeled against published pharmacokinetic data — never against trend.
Blended and encapsulated in a cGMP-registered facility under HEPA-filtered air, at moisture and temperature tolerances documented per lot.
Every batch is released only after independent identity, potency, heavy-metal and microbial testing. Reports are public by lot number.
Every formulation belongs to one of four lines, defined by clinical intent rather than marketing.
01 / 04Foundational formulations for long-term physiological maintenance.
Explore →
02 / 04Higher-strength, condition-specific formulations for targeted support.
Explore →
03 / 04Longevity-focused formulations grounded in cellular-aging research.
Explore →
04 / 04Cognitive and physical performance formulations for sustained demand.
Explore →
C-01FINORA Core
400 mg · Chelated
400 mg fully chelated magnesium glycinate — dosed to match clinical research, not rounded down for margin.
V-03FINORA Vita
300 mg · Nicotinamide Riboside
300 mg pharmaceutical-grade nicotinamide riboside with trans-resveratrol cofactor. HPLC-assayed per lot.
P-02FINORA Performance
1000 mg EPA/DHA
1000 mg combined EPA/DHA in triglyceride form. IFOS-tested, oxidation index below 8.
K-05FINORA Clinical
500 mg · Phospholipid Complex
500 mg phytosome-bound curcumin for 29× bioavailability versus standardised extract. Dosed for daily clinical use.
Named clinicians, each speaking to a specific formulation they've engaged with in practice. No anonymous praise — perspectives, on the record.
| Attribute | FINORA Nutra | Premium Retail | Mass Market |
|---|---|---|---|
| Manufacturing | cGMP + pharmaceutical audit | cGMP | Contract blend |
| Third-party testing | Every lot, published | Occasional | Not disclosed |
| Assay tolerance | ±2% | ±10% | Not stated |
| Active form | Bioidentical / methylated | Mixed | Synthetic |
| Excipients | Zero fillers | Minimal | Common |
| Traceability | Botanical to bottle | Supplier level | Aggregate |
Independent bodies inspect the facility, the formulation, and the finished lot.
Begin with the Foundational series, or speak with a member of our clinical team about a protocol tailored to your practice.
One clear, well-sourced note a month. No hype, no daily inbox noise.